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1 Introduction 
1.1 Tumor Hypoxia 
Hypoxia is a common feature in advanced solid tumors. Hypoxic tissue areas 
have been found in a variety of different tumors such as breast cancer, head and 
neck cancer and soft tissue sarcomas1–4. Hypoxia is not only detected in locally 
advanced or metastatic tumors but also in premalignant lesions or small tumors5 
and plays an important role in the evolutionary process of carcinogenesis6,7. 
Mean pO2 in tumors is generally reduced compared to normal tissue and most 
tumors show areas where pO2 is lower than 5 mmHg8,9. 
Tumor hypoxia results from an imbalance between oxygen consumption and 
oxygen supply, mainly caused by morphologically abnormal vessels8. Besides an 
abnormal vessel wall10, they often show twisting and bending, arteriovenous 
shunts and sinusoidal parts11. Together with a heterogeneous distribution, these 
abnormalities lead to functional problems resulting in an unstable direction and 
speed of flow, microthrombosis and arteriovenous shunt perfusion, leading to 
insufficient oxygen supply8. This perfusion-related or ischemic hypoxia is called 
acute hypoxia. It mainly is a transient effect and can lead to reoxygenation 
injury12,13. 
Besides perfusion-related hypoxia, diffusion-related hypoxia also contributes to a 
reduced supply with oxygen and other nutrients in cells more than 70 µm distant 
from vessels14. Hypoxic conditions (pO2 < 5 mmHg) can be found at distances 
around 70-80 µm from a vessel, near anoxic conditions (pO2 < 0.5 mmHg) are 
normally found more than 150 µm away from vessels9. This is consistent with 
findings that there are no viable tumor cells at distances greater than 160 µm 
from vessels and there are heterogeneous distributed areas with chronic hypoxia 
in tumors15,16. 
Additionally, a limited O2 transportation capacity in cancer patients can aggravate 
hypoxic conditions in tumor tissues17. Anemia is a common condition in patients 
suffering from cancer and is often seen as a side effect of cytostatic treatment. 
Furthermore, numerous other factors like chronic inflammation, hypersplenism, 
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tumor-associated bleeding and nutritional deficiencies18 contribute to a further 
reduction in hemoglobin levels in cancer patients. 
In normal tissue, hypoxia normally leads to cell cycle arrest and inhibition of 
mRNA translation to prevent the cells from further damage19,20. Prolonged 
hypoxic states or anoxic conditions often lead to cell death via apoptosis or 
necrosis21. Though tumor cells are normally more resistant to hypoxic stress22, 
they are not completely immune to hypoxic damage23. Additionally, 
reoxygenation can contribute to cell death after hypoxic episodes by several 
mechanisms such as activation of FAS-dependent death pathways, 
mitochondrial damage13 or formation of reactive oxygen species (ROS)24. 
To evade cell death and cell cycle arrest, some cells have achieved a number of 
mechanisms to survive in a hypoxic environment. Generally, hypoxia activates 
several survival pathways including HIF-1- and NF-κB-signalling25, which enable 
cells to evade apoptosis and which are often altered in tumor cells26. Among 
others, tolerance to chronic or intermittent hypoxia has been associated with loss 
of the tumor suppressor p53, upregulation of free radical scavenging systems, 
and deregulated expression of antiapoptotic proteins of the Bcl-2 family6,27. 
 
1.2 Hypoxia and Tumorigenesis 
Today, tumorigenesis is seen as a multistep development based on spontaneous 
mutations which enables cells to grow with tumor specific characteristics. In the 
year 2000, D. Hanahan defined six characteristic biological capabilities, the 
“Hallmarks of Cancer”, which can be seen in almost any kind of cancer7 (Figure 
1). They include sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis.  
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In 2011, based on further development in cancer research, he added 
reprogramming of energy metabolism, evading immune destruction, tumor 
promoting inflammation and genome instability  as further characteristics to his 
widely accepted model28.  
Hypoxia has an influence on several of these hallmarks and tumor hypoxia is 
associated with poor prognosis as seen in several neoplastic entities like head 
and neck cancer29 and soft tissue sarcomas30,31. Referring to the underlying 
hallmarks, hypoxia has been shown to promote resistance to cell death by 
selection for tumor cells that can evade hypoxia driven apoptosis occurring in the 
early stage of tumor development. This, for example, includes cells with loss of 
the tumor suppressor p536 or upregulation of the antiapoptotic protein IAP-227 
followed by a resistance to HIF-1 mediated cell death26. On the other hand, HIF-
1 is also a driver of proliferation as a second hallmark and is often expressed on 
a high level in tumor cells32. HIF-1 is known to induce the production of growth 
factors like TGF-β33,34 or PDGF35 as seen in human glioblastoma cells. Besides 
Figure 1 - The Hallmarks of Cancer Typical characteristics of tumors are shown in this widely accepted model of 
tumorigenesis; adapted from Hanahan, D. & Weinberg, R. a. Hallmarks of cancer: the next generation. Cell 144, 
646–74 (2011), Copyright © 2011 Elsevier Inc  
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HIF-1, there are other hypoxia induced pathways that promote proliferation like 
the PI3K/Akt/GSK-3 pathway36,37. 
According to Hanahan, the induction of angiogenesis is another hallmark of 
neoplastic disease. As tumors are fast growing tissues, there is a need for 
sufficient supply with nutrients and oxygen and vascularization as described 
above. There are several pathways upregulated in a variety of tumors that 
promote the angiogenetic switch either in a hypoxia dependent or hypoxia 
independent way38–40. One of the most important factors regarding angiogenesis 
is VEGF, which is secreted in a HIF-dependent manner and is known to be 
upregulated in different tumors41. Even though VEGF has been shown to be an 
effective target for cancer therapy with antiangiogenetic drugs like 
bevacizumab42, VEGF-induced angiogenesis is not a crucial pathway for tumor 
development43. 
Invasion and metastasis are further steps that are prompted by hypoxia. Hypoxic 
tumors are more likely to show distant metastasis3,44. This process, among other 
steps, includes epithelial to mesenchymal transition (EMT) characterized by the 
hypoxia-induced loss of E-cadherin45,46. Further steps are an increased tumor cell 
migration and metastatic homing resulting from the hypoxia-dependent 
overexpression of lysyl oxidase (LOX)47 and chemokine receptor CXCR448,49. 
The deregulated growth in neoplastic disease additionally involves adjustments 
of energy metabolism. This effect was initially described by Otto Warburg50,51 who 
found tumor cells to limit their energy production to glycolysis and lactic acid 
fermentation even under aerobic conditions. These adjustments are driven on the 
one hand by the tumor microenvironment that selects for cells capable of handling 
varying oxygen supply and on the other hand by oncogene activation that cause 
changes in metabolism28,52. The reprogramming of metabolism provides cells 
with substrates for biosynthetic pathways53,54 that are more efficient than 
oxidative phosphorylation regarding the needs for active cell proliferation. Similar 
adaptions of cell metabolism can be seen during embryogenesis55. Additionally, 
changes in metabolism affect apoptosis pathways56 and might be involved in local 
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signaling supporting tumor proliferation57 or leading to increased 
angiogenesis58,59.  
 
1.3 Hypoxia – Reoxygenation Injury 
Whereas short or moderate hypoxia is known to result mainly in cell cycle 
arrest19,25, severe hypoxia might also induce necrosis or apoptosis via 
cytochrome C release, caspase 9 activation and the following activation of 
effector caspases resulting in cell death23,60. However, not only oxygen 
deprivation but also reoxygenation can cause cellular damage. This so called 
reperfusion injury is a widely seen phenomenon in myocardial infarction or stroke, 
and also after reperfusion of transplanted organs61. Besides sterile inflammation 
mediated for example by TLR462, reactive oxygen species (ROS) significantly 
contribute to reoxygenation injuries. Oxidative stress may be triggered by Ca2+ 
overload of the mitochondria, concomitant hyperpolarization of the voltage (m) 
across the inner mitochondrial membrane and and may result in superoxide 
formation63,64. Under physiological conditions, these oxygen radicals are 
eliminated by superoxide dismutase (SOD). ROS generation exceeding 
detoxification generates excessive hydroxyl radicals, which have a high potential 
of damaging cellular structures, enzymes or channel proteins on the cellular 
membrane, finally leading to cell death65. To cope with oxidative stress, 
cells/organs have developed a variety of antioxidant defense mechanisms, 
including preventative mechanisms, repair mechanisms, physical defenses and 
antioxidant defenses66. These mechanisms are responsible for an effect called 
preconditioning, which describes the phenomenon that cells/organs that are 
repetitively exposed to cycles of non-lethal hypoxia/reoxygenation (H/R) are less 
affected by a subsequent phase of severe hypoxia/reoxygenation. This effect has 
first been described as “warm-up phenomenon” in angina pectoris67 and been 
further evaluated in a variety of models68. It involves for example HIF-1 dependent 
mechanisms69, adenosine signalling70 and also ROS induced mechanisms71,72.  
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1.4 Irradiation Effects 
Irradiation is besides chemotherapy and surgery the third basis of cancer 
treatment and is included in about 50% of all cancer treatment concepts73,74. It is 
used for example to support chemotherapy, prevent local recurrence or pretreat 
tumors before surgery. Irradiation works by inducing cell death via a number of 
different ways. The main mechanisms are direct and indirect induction of DNA 
strand lesions that lead, if not repaired, to cell death via apoptosis or necrosis75–
77 and generation of reactive oxygen species (ROS) causing DNA and cell 
damage66,78. Long term effects of irradiation include genomic instability and 
bystander effects79,80, that could lead to cell death, as well as modulation of the 
immune system and the tumor microenvironment81. Regarding tumor hypoxia, 
there is a clinically relevant oxygen enhancement effect82,83 affecting the 
susceptibility of tumors to irradiation. This is based on a higher rate of ROS 
induction and a higher rate of interaction with DNA in the presence of oxygen78,84. 
Furthermore, DNA-damage repair mechanisms work more efficient in the 
absence of oxygen82. Additionally, tolerance to chronic intermittent hypoxia has 
been associated with loss of the tumor suppressor p53, upregulation of free 
radical scavenging systems, and deregulated expression of antiapoptotic 
proteins of the Bcl-2 family, promoting a crossresistance to irradiation6,85,86. The 
increase in radical scavenging systems is of particular therapeutical interest, 
because low cellular ROS-levels have been associated with radiation resistance, 
e.g. in glioma stem cells87. 
 
1.5 Reactive Oxygen Species 
Reactive oxygen species (ROS) are chemically highly reactive molecules 
containing oxygen88,89. The most important forms are superoxide and besides 
that hydroxyl and peroxyl radicals, which are inductors of secondary ROS90. The 
majority of ROS are produced during mitochondrial respiration. Complex I (NADH 
oxidase) and III (cytochrome C reductase) of the mitochondrial electron transport 
chain may leak single electrons to molecular oxygen. By that electron leakage, 
1-2% of total molecular oxygen consumed by normal respiration is converted into 
the relatively stable superoxide anion (𝑂2
−). Dismutation of 𝑂2
− by superoxide 
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dismutase produces H2O2. Subsequent interaction of H2O2 and 𝑂2
− or Fe2+- or 
Cu2+-driven cleavage of H2O2 can generate the highly reactive hydroxyl radical 
(OH-·)91,92.  
Both the rate and the efficiency of the oxidative phosphorylation are regulated by 
the substrates of the mitochondrial respiratory chain and by the efficacy and 
activity of the proton transport complexes I, II, IV and V of the respiratory chain. 
Additionally, extrinsic uncoupling, i.e. transport processes which lower the proton 
motive force across the inner mitochondrial membrane but do not belong to the 
respiratory chain, has a significant influence on oxidative phosphorylation. 
Activity and efficacy of these proton pumps are mainly fine-tuned by the 
dependence of the ATP synthase (complex V) on the membrane potential ∆Ψm, 
the ATP/ADP ratio, as well as by reversible phosphorylation of the complexes I 
and IV93. It is suggested that under physiological conditions, i.e. high ATP/ADP 
ratios, the membrane potential ∆Ψm is kept low through the potential dependence 
of the ATP synthase and the allosteric inhibition of phosphorylated cytochrome C 
oxidase (complex IV). The efficacy of the respiratory chain at low ∆Ψm is high. At 
higher ATP demand or decreasing cellular ATP levels, cytochrome C oxidase is 
relieved from ATP blockade and ∆Ψm increases. High ∆Ψm values, however, 
lower the efficacy of cytochrome C oxidase and increase the probability of single 
electron leakage at complex I and III to molecular oxygen resulting in an 
increased O2- production93–95. 
Besides mitochondria, there are also other sources of ROS. Certain enzymes 
produce ROS for physiological uses for example in peroxisomes for 
degradation89 of macromolecules. It is further known that under certain metabolic 
conditions the production of ROS is increased96. Hyperglycemia for example can 
cause oxidative stress by increased ROS formation, which results in vascular 
damage and an increased risk for cardiovascular disease97. Furthermore, as 
mentioned above, hypoxia/reoxygenation injury is mainly mediated by increased 
ROS production during the hypoxic period and especially after 
reoxygenation12,98,99.  
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Cancer therapy is another source of increased oxidative stress. As described 
above, irradiation is a direct and indirect source of ROS causing DNA damage 
and cell death78. Chemotherapeutics like actinomycin D and cisplatin are also 
known to increase ROS generation leading to additional cell damage besides 
their primary mode of action100. 
Reactive oxygen species have different physiological and pathophysiological 
functions in cell signaling and metabolism. Physiologically, they are mainly 
involved in signaling pathways regarding cell growth and differentiation. This 
includes for example oxygen homeostasis via the induction of HIF-1, VEGF101,102 
and cell adhesion103. Inflammation is another important process ROS are 
involved in. The so-called oxidative burst is a massive production of ROS by 
activated neutrophils and macrophages and plays a key role in defence against 
environmental pathogens. These cells produce large quantities of superoxide 
radicals and other ROS via the NADPH oxidase104 and myeloperoxidase105. 
Aside from that ROS, are important for the activation of the immune response via 
T-cell activation following long term immunity106. 
Furthermore, reactive oxygen species are involved in the process of apoptosis, 
not only as an inductor but also during the activation phase107. 
Negative effects of reactive oxygen species can be summarized under the term 
oxidative stress. It results from the secondary oxidation of DNA, proteins and 
lipids89,90. Oxidative stress is known to be involved in aging and numerous 
diseases like cancer and cardiovascular disease66 and can be quantified by 
validated biomarkers108. In cardiovascular disease for example, oxidative stress 
plays a role in hypoxia/reoxygenation injury as mentioned above but also in ROS 
mediated Ca2+-overload and subsequent cell injury109. Compared to their normal 
counterparts, cancer cells produce higher levels of ROS110,111 and are known to 
be adapted to the resulting oxidative stress to a certain degree112. The level of 
oxidative stress determines the consequences regarding tumor promotion, 
mutagenesis and cell death66 as presented in the following diagram (Figure 2). 
Introduction 18 
 
As shown in the diagram, low or moderate oxidative stress is involved in 
mutagenesis leading to cancer. This thesis is supported by the fact that agents 
like cadmium113, arsenic114 or tobacco smoke115 are known to increase free 
radical formation leading to DNA damage, higher mutation rate and cancer116.  
With regards to cancer progression, there is a certain imbalance in redox 
homeostasis in cancer cells compared to normal tissue66 which promotes some 
of the hallmark characteristics described above. Growth signaling is enhanced by 
ROS via NFκB-signaling117 or MAP-kinase118,119 and angiogenesis can be 
promoted by ROS dependent stabilization of HIF-1 and VEGF102. Invasion and 
metastasis as another hallmark of cancer is stimulated by free radicals via an 
increased expression of MMP2120 and EGFR121 and resulting epithelial to 
mesenchymal transition 122. 
Level of oxidative stress
Moderate HighLow
Apoptosis/
Necrosis
MutagenesisTumor
promotion
Figure 2 - Effect of Oxidative Stress on Tumorigenesis; adapted from Valko et al. Free radicals and 
antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39, 44–84 
(2007), Copyright © 2007 Elsevier Inc. 
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As in normal cells, levels of ROS exceeding a certain amount lead to cell death 
in tumor cells. Considering the higher intrinsic oxidative stress, tumor cells have 
developed a number of adaptive responses to prevent cellular damage. Many 
tumor cells exhibit increased levels of antioxidants like thioredoxin peroxidase123 
or gluthation that are partially under the control of signaling pathways related to 
proliferation like c-myc124. Another way of evading cell damage are alterations of 
cell death pathways like ROS induced changes in the PI3K/Akt signaling125. 
Adaptions are promoted by ROS induced genetic instability and clonal selection 
of more resistant cells supporting a vicious circle leading to tumor cells that are 
adapted to high levels of oxidative stress as shown in the following scheme 
(Figure 3).  
 
Another way of adaption to high levels of oxidative stress could be to establish 
ways of reducing the formation of free radicals in situations where high amounts 
of ROS are generated like hypoxia/reoxygenation or irradiation.  
Since mitochondrial ROS formation increases with increasing ∆Ψm 93–95, lowering 
of the mitochondrial ∆Ψm is proposed to be a key adaptation event in ischemic 
Figure 3 - The Vicious Circle of ROS Stress in Cancer  from Trachootham et al. Targeting cancer cells by 
ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews. Drug discovery. 8, 579-91 
(2009), Copyright © 2009 Macmillan Publishers Limited112. 
Introduction 20 
preconditioning126. Lowering of ∆Ψm reduces not only mitochondrial 𝑂2
− 
production but also the mitochondrial Ca2+-overload during reoxygenation127,128. 
The hypoxic preconditioning-associated reduction of ∆Ψm is partially achieved by 
up-regulation of ATP-sensitive (mitoKATP) and Ca2+-activated (mitoKCa) K+ 
channels in the inner mitochondrial membrane which short-circuit ∆Ψm127–129. 
 
1.6 Uncoupling Proteins 
Further proteins that contribute to depolarization of ∆Ψm are a family of proteins 
called uncoupling proteins (UCP). This class of proteins was first described when 
a leak of protons was detected in isolated mitochondria from brown adipose 
tissue130. UCP-1, the first described protein131 of this family was identified as a 32 
kDa proton carrier that was responsible for uncoupling in brown adipose tissue 
promoting thermogenesis. Following this, more uncoupling proteins were 
discovered. Up to now, there were five UCPs described in mammals, with UCP 
1, 2 and 3 showing high sequence identity and a molecular weight between 31-
34 kDa whereas UCP 4 and 5 being quite different132. In contrast to UCP-1 which 
is highly expressed in brown adipose tissue, UCP-2 is expressed in various 
human tissues, whereas UCP-3 is mainly expressed in skeletal muscle and heart 
tissue132,133. As RNA expression does not necessarily predict protein expression 
of UCP-2/3, it is crucial that changes in the cellular rate of RNA-expression are 
confirmed at the protein level if a biochemical or physiological role for either of 
these proteins is to be claimed134,135. Regulation and activation of UCP-2 and -3 
are a matter of ongoing debates. Both proteins have been shown to be activated 
by superoxide with the exact mechanism still unknown. Theoretically, superoxide 
could either directly activate UCPs or via intermediates like hydroxynonenal136,137. 
Expression control of UCP-2 and -3 is known to be influenced by fatty acids138 
indicating a contribution of UCPs in fatty acid metabolism. High expression of 
UCP-3 has been demonstrated in skeletal muscle where it suppresses 
mitochondrial oxidant emission during fatty acid-supported respiration139 and 
after anaerobic muscle contraction140,141. Accordingly, overexpression of UCP-3 
in cultured human muscle cells lowers ∆Ψm, raises the ATP/ADP ratio, and 
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favours fatty acid instead of glucose oxidation142. Hypoxia is another known 
inductor of UCP-3 expression in a p38 MAP kinase/ATF-1 dependent way143,144. 
The function of UCPs has controversially been discussed. Initially, a role in 
mitochondrial proton leak was questioned since UCP-2/3 knock-out mice in 
contrast to UCP-1 knockout mice do not show a significant lack in 
thermogenesis138,145. Later on, it has been shown that under physiological 
conditions UCP-2/3 only cause a depolarization of m  of 15 mV described as 
mild uncoupling146,147 whereas under unphysiological conditions UCP-3 can also 
contribute to thermogenesis148. A second thesis is that UCP-2/3 are mainly 
involved in ROS metabolism, which is supported by many studies. It has been 
shown that a moderate decrease of m can significantly lower ROS 
production93–95. As superoxide activates UCPs, they could be effectors of a 
feedback loop which restricts overshooting ROS production136 both in isolated 
mitochondria and in intact cells149,150. This is supported by findings of elevated 
ROS in UCP-2/3-deficient mice145,151 and an increase in oxidative damage in 
UCP-3-deficient mice152. Based on the function of reducing oxidative stress, 
UCP-2/3 have been shown to be involved in a number of processes that are 
related to ROS production like aging153 and diabetes154,155. As described above, 
hypoxia/reperfusion injury is mainly caused by increased production of ROS. 
Besides other factors, UCPs contribute to ischemic tolerance both in stroke156 
and myocardial infarction157 and are involved in ischemic 
preconditioning126,158,159. Regarding oxidative stress in cancer, UCP-2 has been 
identified as an antiapoptotic protein preventing cancer cells from ROS-induced 
cell death after exposure to hypoxia or menadione160,161. It has also been shown 
to reduce the effect of many antineoplastic drugs including doxorubicin, 
gemcitabine and cisplatin162–164 and its expression is increased in colon cancers 
correlating with the degree of neoplastic changes165. Concerning the influence of 
UCP-3 on cell death and cancer, similar studies have not been published yet. 
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1.7 Aim of the Study 
“The present study aimed to define mechanisms of hypoxia/reoxygenation 
adaptation in vitro by comparing H/R-adapted with highly hypoxia-sensitive 
parental cells. For H/R adaptation, immortalized primary cultures of mouse 
proximal convoluted tubule cells (PT) which are highly dependent on oxidative 
respiration and therefore highly hypoxia-sensitive were subjected to repeated 
cycles of hypoxia and reoxygenation. That way H/R-adapted PT cultures were 
then compared with the continuously normoxic-grown parental control cells in 
terms of H/R- and radiotherapy-induced impairment of mitochondrial function, 
formation of reactive oxygen species (ROS), cell death and gene expression with 
a focus on UCP-3-mediated effects.  
To estimate whether this in vitro findings might be translated to the in vivo 
situation, the present study in a second step analyzed UCP-3 expression in PT-
derived clear cell renal cell carcinoma.” 
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2 Material and Methods 
2.1 Selection of Partial Hypoxia/Reoxygenation (H/R) - resistant Proximal 
Convoluted Tubules (PT) Cells. 
“PT were microdissected from newborn mice as described elsewhere166. PT cells 
were immortalized by SV40 large T-antigen transformation167 as accomplished 
by transfection with SV3 neo, selected in geneticin-containing medium and 
cultured on collagenated surfaces in equal quantities of DMEM and Ham’s F-12 
(GIBCO) medium containing 1 mM NaHCO3 (GIBCO), 5% FCS (Biochrom), 2.5 
mM glutamine, 2.5 mg/l insulin, 2.5 mg/l transferrin, 15 nM sodiumselenite (ITSS 
Supplement, Roche Diagnostics), 25 nM dexamethasone (Sigma Aldrich), 5 ng/l 
epidermal growth factor (Calbiochem) and G418-BC (60U/ml, Biochrom) at 37°C 
with 5% CO2. As shown below (Figure 4), four parallel cultures of PT cells were 
passaged (once per week) for 12 weeks. In this period of time, cells where weekly 
subjected to hypoxia (0.1% oxygen for 48 h starting 2-3 d after passaging the 
cells applied by the BD GasPak EZ Pouch System (Becton and Dickinson). For 
control, further four PT cultures were grown under continuous normoxia, 
passaged twice weekly for 12 weeks. Thereafter, all cultures were passaged 
twice to increase cell number, aliquoted and frozen.” Three cultures were then 
selected for further testing168. 
Figure 4 - Selection Protocol for H/R-resistant Cells Repetitive exposure to hypoxia/reoxygenation (H/R) 
selected partial H/R-resistent proximal convoluted tubule (PT) cells. 168 
2 d hypoxia
5 d normoxia
12 selection cycles
selected
control
immortalized
PT cells
continuous normoxia
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2.2 Freezing and Thawing 
Long-time storage of cells was done at -196°C in liquid nitrogen. For freezing 1 x 
106 – 3 x 106 cells were resuspended in normal growth medium supplemented 
with 10% FCS and 10% DMSO (Sigma), aliquoted and frozen using a Nalgene® 
Mr. Frosty at –80°C overnight and then stored in liquid nitrogen.  
After thawing cells were washed with medium to remove DMSO and then 
cultivated in normal growth medium. Cells were passaged at least once before 
using them for further testing. 
 
2.3 H/R- and Radiation-induced Cell Death 
“To test for an acquired hypoxia resistance, subconfluent H/R-adapted and 
control cultures were grown for 48 h under normoxia or hypoxia (0.1% oxygen) 
followed by 0.5, 24 or 48 h of reoxygenation. To test for radiation resistance, in 
further experiments H/R-adapted and control cultures were irradiated with single 
doses of 0, 5, or 10 Gy photons by a linear accelerator (LINAC SL25 Philips) at 
a dose rate of 4 Gy/min at room temperature under normoxic conditions. 
Following irradiation, cells were postincubated in supplemented medium for 24 h 
or 48 h. H/R-treated or irradiated cells were trypsinated and then permeabilized 
and stained (30 min at room temperature) with propidiumiodide (PI) solution 
(containing 0.1% Na-citrate, 0.1% triton X-100, 10 μg/ml PI in phosphate-buffered 
saline, (PBS)) and the DNA amount was analyzed by flow cytometry (FACS 
Calibur, Becton Dickinson, Heidelberg, Germany, 488 nm excitation wavelength) 
in fluorescence channel FL-2 (logarithmic scale, 564-606 nm emission 
wavelength)169. The subG1 population in the PI histogram defined dead cells with 
degraded DNA. Data was analyzed with the FCS Express 3 software (De Novo 
Software, Los Angeles, CA, USA).168” 
Furthermore, adherent cells were stained (10 min, 37°C) with Hoechst 33342 
(Calbiochem; 1.5 nM) and PI (Sigma-Aldrich, 0.5 nM) after exposure to hypoxia 
(48 h) and reoxygenation (24h) and cell death was evaluated by fluorescence 
microscopy (Axiovert 25, Carl Zeis, Jena, Germany). Pictures of three areas in 
every culture dish were taken (Canon EOS 500D) and vital and dead cells were 
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counted. Vital cells are only stained with Hoechst 33342 as the PI is excluded by 
the intact cell membrane and have an oval-shaped blue nucleus. Apoptotic cells 
typically contain several fragmented blue or in late apoptosis red bodies. Necrotic 
cells appear as cells with a red nucleus that is round in shape170. Examples are 
shown in the pictures below. 
 
Figure 5 - Hoechst/PI Staining Representative examples showing vital and dead (apoptotic and necrotic) 
cells after Hoechst 33342/PI staining (Axiovert 25, Carl Zeiss; 20x; Canon EOS 500D; Canon EOS Utility) 
 
2.4 Inner Mitochondrial Membrane Potential (m). 
“To determine m, hypoxia (48 h)/reoxygenation (24 h)-subjected as well as 
normoxic grown H/R-adapted and control PT cultures were trypsinated, washed 
and incubated for 30 min at room temperature in a NaCl solution (in mM: 125 
NaCl, 5 D-glucose, 5 KCl, 1 MgCl2, 1 CaCl2, 32 N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid (HEPES) titrated with NaOH to pH 7.4) containing the m 
specific dye tetramethylrhodamine ethyl ester perchlorate (TMRE, 25 nM, 
Invitrogen). m was analyzed by flow cytometry in FL-2 in the absence or 
presence of the proton ionophore carbonyl cyanide-3-chlorophenylhydrazone 
(CCCP, 1 μM) as a control for dissipated m. Data was analyzed with the FCS 
Express 3 software (De Novo Software, Los Angeles, CA, USA).168” 
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2.5 Formation of Reactive Oxygen Species (ROS) and Mitochondrial ROS. 
To test for production of ROS, control or H/R-adapted PT cells were pretreated 
(normoxia or hypoxia (48 h)/ reoxygenation (24 h)), detached, incubated for 30 
min at room temperature in NaCl solution (see above) containing 10 μM of the 
redox-sensitive dye 5-(and-6)-chloromethyl-2'7'-dichlorodihydrofluorescein-
diacetate acetyl ester (CM-H2DCFDA, Invitrogen) and ROS-specific fluorescence 
was recorded by flow cytometry in Fl-1 (515-545 nm emission wavelength)171,172. 
To test for fluorescence dye loading, control samples were oxidized (1 mM tert-
butylhydroperoxide) for 15 min and recorded. 
“To test for mitochondrial production of superoxide anion as the most common 
mitochondrial ROS, control or H/R-adapted PT cells were pretreated (normoxia 
or hypoxia (48 h)/ reoxygenation (24 h)), detached, incubated for 10 min at 37°C 
in NaCl solution (see above) containing 5 µM of an superoxide anion-sensitive 
dye (MitoSOX, Invitrogen)173, and specific fluorescence was recorded by flow 
cytometry in Fl-2. To test for fluorescence dye loading, control samples were 
oxidized (1 mM tert-butylhydroperoxide) for 30 min and recorded168.” 
 
2.6 Quantitative RT-PCR 
“Messenger RNAs of H/R-adapted and control PT cultures (normoxic and after 
hypoxia (48 h)/ reoxygenation (24 h)) were isolated (Qiagen RNA extraction kit, 
Hilden, Germany) and reversely transcribed in cDNA (RT² First Strand Kit, 
SABiosciences, Qiagen)” according to the manufacturers protocols. Quality 
control and DNA content was evaluated photometrically using a 
Nanodrop1000174 (Thermo Fisher). Fragments of interest were amplified by the 
use of PCR arrays (RT ProfilerPCR ArrayPAMM-012 (Apoptosis) and PAMM-065 
(Oxidative Stress), SABiosciences, Qiagen, Hilden, Germany) and a Roche Light 
Cycler 480 according to the manufacturer’s instructions and using the following 
PCR protocoll.”  
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“Ct (threshold cycle) values of the PCR amplifications were normalized to those 
of the housekeeper genes. Mouse UCP-3 and GAPDH specific cDNAs were 
additionally amplified by QuantiTect Primer Assays (#QT00115339 and 
QT01658692, respectively, Qiagen)” and the Roche Light Cycler 480 for further 
evaluation168. 
 
2.7 Transfection with siRNA 
“Adherent PT cells were grown in normal medium and transfected at 60% 
confluence with a transfection reagent (TransIT-TKO, Mirus Bio, Madison, WI, 
USA) according to the manufacturer’s protocol. UCP-3 siRNA and non-targeting 
siRNA (ONTARGETplusSMARTpool, ON-TARGET Non-targeting siRNA, 
ThermoScientificDharmacon, Chicago, IL, USA) were used at a final 
concentration of 50 nM. Transfection efficiency and viability was determined by 
transfecting the cells with 400 nM green fluorescence siGLO siRNA 
(ThermoScientificDharmacon) followed by propidium iodide exclusion dye and 
flow cytometric analysis. Immediately after transfection, cells were cultured either 
under normoxia or hypoxia (48 h).” Irradiation after downregulation with siRNA 
was done 24 h after transfection. “Downregulation of UCP-3 was controlled by 
immunoblotting.” Cell death and ROS formation was evaluated with flow-
cytometry as described above after 24 h of reoxygenation or 24 h post 
irradiation168.  
 
Programm  Cycles Temperature 
(°C) 
Time 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Start 1 95 00:10:00 4,4 
Quantification 40 95 
65 
00:00:15 
00:01:00 
4,4 
2,2 
Melting Curve 1 95 
65 
95 
00:00:10 
00:01:00 
 
4,4 
2,2 
0,11 
Cooling 1 40 00:00:10 1,5 
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2.8 Immunoblotting 
“Following normoxia or hypoxia (48 h)/ reoxygenation (24 h) H/R-adapted and 
control PT cultures as well as freshly frozen specimens from dissected human 
renal cell carcinoma with adjacent normal renal tissue (patients gave informed 
consent and the experiments were approved by the ethical committee) were lysed 
in a buffer (containing in mM: 50 HEPES pH 7.5, 150 NaCl, 1 EDTA, 10 sodium 
pyrophosphate, 10 NaF, 2 Na3VO4, 1 phenylmethylsulfonylfluorid (PMSF) 
additionally containing 1% triton X-100, 5 μg/ml aprotinin, 5 μg/ml leupeptin, and 
3 μg/ml pepstatin) and separated by SDS-PAGE under reducing condition. 
Segregated proteins were electro-transferred onto PVDF membranes (Roth, 
Karlsruhe, Germany). Blots were blocked in TBS buffer containing 0.05% tween 
20 and 5% non-fat dry milk for 1 h at room temperature. The membrane was 
incubated overnight at 4°C with rabbit anti-UCP antibody 1:1000 (anti UCP-3 
#ab3477, anti-UCP-1 #ab57687 or anti UCP-2 #ab67241, Abcam, Cambridge, 
UK). Equal gel loading was verified by an antibody against β-actin (mouse anti-
β-actin antibody, clone AC-74, Sigma #A22281:20,000) or GAPDH (mouse anti 
GAPDH, #ab8245 clone 6C5, Abcam, 1:20,000)” as well as PageBlue™ Protein 
Staining Solution (ThermoFisher). “Antibody binding was detected with a 
horseradish peroxidase-linked goat anti-rabbit or horse anti-mouse IgG antibody 
(Cell Signaling # 7074 and #7076, New EnglandBiolabs, 1:1000 and 1:2000 
dilution in TBS-Tween/5% milk, respectively) incubated for 1 h at room 
temperature and enhanced chemoluminescence (ECL Western blotting analysis 
system, GE Healthcare/Amersham-Biosciences, Freiburg, Germany). Where 
indicated, protein levels were quantified by densitometry using ImageJ software 
(ImageJ 1.40g NIH, USA). UCP-3 expression of the tumor samples was semi-
quantified using an arbitrary score from 0 (not expressed) to 4 (highest 
expression)168.”  
 
2.9 Statistics  
“Given data are means ± standard error (SE). Differences between experimental 
groups were assessed by (Welch-corrected) two-tailed student t-test or ANOVA 
where appropriate. P values of ≤ 0.05 were defined as significant.”   
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3 Results 
3.1 Selection of Partial H/R-resistant Proximal Convoluted Tubule (PT) 
Cells 
“Four parallel cultures of PT cells were passaged (once per week) for 12 weeks. 
During this period, cells where subjected to weekly cycles of hypoxia (0.1% 
oxygen for 48 h) and reoxygenation (5 days). Each cycle started 2-3 d after 
passaging the cells. As a control, further four PT cultures were grown under 
continuous normoxia and passaged twice weekly for 12 weeks. Thereafter, all 
cultures were passaged twice to increase the cell number, aliquoted and frozen. 
To test for an acquired H/R resistance, sub-confluent H/R-adapted and control 
cultures were grown for 48 h under normoxia or hypoxia (0.1% oxygen) followed 
by 0.5, 24 or 48 h of reoxygenation. Thereafter, the DNA of the cells was stained 
with propidium iodide (Nicoletti protocol). H/R induced a G2/M cell cycle arrest in 
both control and H/R-adapted PT cells, suggestive of H/R-causing genotoxic 
stress. In addition, H/R resulted in cell death as defined by the subG1 population 
of the propidiumiodide histogram (Figure 6)168.”  
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Figure 6 - PI Staining after Hypoxia/Reoxygenation Histograms showing the propidium iodide 
fluorescence intensity of permeabilized control and H/R-adapted PT cells. Cells were recorded by flow 
cytometry either under control conditions (72 h of normoxia, black line) or after 48 h of hypoxia (0.1% 
oxygen) followed by 24 h of reoxygenation (red line). The marker indicates the dead cells (sub G1 
population). 
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“Cell death induction was dependent on reoxygenation time (Figure 7). Most 
importantly, cell death was significantly reduced in the H/R-adapted cells as 
compared to the control cultures indicating acquisition of a partial H/R resistance 
during the selection time.”  
 
 
Significant difference in the percentage of cell death after 48 h was confirmed by 
staining with Hoechst 33342/PI (Figure 8). There was also seen a cycle-
dependent increase in the partial H/R resistance during the selection process. 
Figure 7 - Influence of Reperfusion Time on Cell Death Mean percentage (± SE, n = 24 from 4 cultures 
each measured in hexaduplicates) of dead cells (sub G1 population) in control (open bars) and H/R-adapted 
cultures (closed bars) grown under normoxia (left) or under hypoxia (48 h of 0.1% oxygen) followed by 0.5 
h (left), 24 h (middle) and 48 h (right) of reoxygenation. * and *** indicate p ≤ 0.05 and p ≤ 0.001, respectively 
(ANOVA). 
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Figure 8 - Hoechst/PI Staining and Time Course of Resistance Acquisition A Mean percentage (+/- 
SE, n = 27 from 3 cultures each measured in triplicates ) of dead cells (apoptotic or necrotic in Hoechst/PI 
staining) in control (open bars) and H/R-adapted cultures (closed bars) grown under normoxia (left) or 
hypoxia (48h of 0.1% oxygen, 48h reoxygenation);* indicates p ≤ 0.05  B Time course of resistance 
acquisition. Shown is the selection-cycle-dependent H/R-induced cell death of the H/R-adapted cultures 
normalized to that of the particular control cultures (means ± SE, n = 4; * indicates p ≤ 0.05 (ANOVA))). 
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3.2 H/R-induced Hyperpolarization of the Inner Mitochondrial Membrane 
Potential (m) 
“Reportedly, reoxygenation may be associated with hyperpolarization of m.63 
We therefore tested for the effect of hypoxia (48 h)/reoxygenation (24 h) on m 
in control and H/R-adapted PT-cultures by flow cytometry applying the voltage-
sensitive fluorescence dye TMRE. H/R induced break-down of m  was seen in 
a significant cell fraction confirming H/R-induced cell death (Figure 9 A). In the 
surviving cells, on the other hand, H/R hyperpolarized m (Figure 9, B and D). 
Markedly, H/R-adapted PT cultures exhibited both significantly less H/R-induced 
m break-down (Figure 9, C) and significantly less m hyperpolarization in the 
surviving cell population (Figure 9, D)168.”  
 
Figure 9 - m Analysis in Flow Cytometry (TMRE staining) After H/R stress, H/R-adapted cultures 
exhibit less hyperpolarization of the inner mitochondrial membrane potential (m) than control cultures and 
less break down of m. A, B. Dot plots (A) and histograms (B) showing forward scatter and 
tetramethylrhodamine-ethyl-ester-perchlorate (TMRE) fluorescence as a measure of cell size and m, 
respectively. Depicted are a control (left) and a H/R-adapted PT culture (right) recorded by flow cytometry 
under normoxic conditions (black lines in B) and after H/R stress (48 h hypoxia / 24 h reoxygenation); (A and 
red histograms in B). Cell populations with dissipated m (low m) are indicated by gate and marker in A 
and B, respectively. (n = 9 from 3 cultures, each determined in triplicates) C, D. Mean percentage of control 
(open bars) and H/R-adapted cells (closed bars) with broken-down m (C) and mean TMRE fluorescence 
intensity of the cell population with high m (D) recorded as in (B) under normoxic conditions (left), after 
H/R stress (48 h hypoxia / 24 h reoxygenation, middle), or after pharmacological break-down of m by the 
proton ionophore carbonyl cyanide-3-chlorophenylhydrazone (CCCP, 1 µM)(right). (± SE, n = 9 from 3 
cultures each determined in triplicate) * and ** indicate p ≤ 0.05 and p ≤ 0.01, respectively (ANOVA) 
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3.3 H/R-induced Formation of Reactive Oxygen Species (ROS) 
ROS formation is known to increase with hyperpolarization of m and can be 
induced by hypoxia/reoxygenation as described elsewhere. We therefore 
analyzed cumulative ROS formation of the control and selected cultures during 
normoxia and after hypoxia (48 h)/reoxygenation (24h) by flow cytometry using 
the redox-sensitive fluorescence dye CM-H2DCFDA. As expected and shown 
below (Figure 10), H/R-induced ROS formation was significantly lower in H/R-
adapted than in control PT cultures. 
 
As we were especially interested in mitochondrial ROS formation, “we analyzed 
mitochondrial superoxide, the most important mitochondrial ROS agent, of the 
control and selected cultures during normoxia and after hypoxia (48 
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Figure 10 - Total ROS Production after H/R H/R produces less reactive oxygen species (ROS) in H/R-
adapted than in control cultures. A. Histograms showing the 5-(and-6)-chloromethyl-2'7'-
dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA) fluorescence as a measure of ROS 
production. PT cells were recorded by flow cytometry from a control (top) and a H/R-adapted culture under 
normoxic conditions (black lines), after H/R stress (48 h hypoxia/24 h reoxygenation, red lines) or after 
oxidation with tertbutylhydroperoxide (tBHP, 1 mM, blue lines). The marker indicates the oxidized cell 
population. B, C. Mean CM-H2DCFDA fluorescence (B) and mean percentage (C) of oxidized cells (± SE, 
n = 6 from 3 cultures each determined in duplicates) recorded as in (A) under normoxic conditions (left), 
after H/R stress (48 h hypoxia / 24 h reoxygenation, middle), or after oxidation with tBHP(right). * and ** 
indicate p ≤ 0.05 and p ≤ 0.01, respectively (ANOVA). 
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h)/reoxygenation (24 h) by flow cytometry using the redox-sensitive fluorescence 
dye MitoSOX. As shown in below (Figure 11), H/R-induced superoxide formation 
was, like total ROS formation; significantly lower in H/R-adapted than in control 
PT cultures168”.  
 
3.4 Gene Expression and Function of Uncoupling Protein-3 (UCP-3) 
“To define candidate genes that might confer H/R resistance, mRNA abundances 
(quantitative RT-PCR microarrays) were compared between control and H/R-
adapted PT cultures after normoxic culture conditions and after hypoxia (48h)/ 
reoxygenation (24 h). Several gene transcripts involved in apoptosis and 
antioxidative defense differed between the control and H/R-adapted PT cultures. 
This suggests that long-term H/R adaptation was accompanied by upregulation 
of oxidative defense, DNA-repair and apoptosis inhibition on the one hand, and 
by an enhancement of the apoptotic cell death machinery on the other. 
H/R-adapted PT cultures constitutively upregulated the anti-apoptotic survivin, 
the caspase-recruitment domain-containing proteins PYCARD and Bcl-10, the 
antioxidative-defense associated thioredoxin reductase and superoxide 
dismutases 2 and 3, the DNA repair enzyme Ataxia telangiectasia and rad3 
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Figure 11 - Mitochondrial ROS Production after H/R H/R induces less mitochondrial ROS in H/R-adapted 
than in control cultures. A. Histograms showing the MitoSOX fluorescence as a measure of mitochondrial 
superoxide production. PT cells were recorded by flow cytometry from a control and a H/R-adapted culture 
under normoxic conditions (black lines), after H/R stress (48 h hypoxia / 24 h reoxygenation, red lines) or 
after oxidation with tertbutylhydroperoxide (tBHP, 1 mM; blue lines). B Mean MitoSOX fluorescence 
intensities recorded as in (A) under normoxic conditions (left), after H/R stress (48 h hypoxia / 24 h 
reoxygenation, middle, data are means ± SE, n = 10-12 from 4 cultures each determined in duplicate or 
triplicate), or after oxidation with tBHP (means ± SE, n = 4 from 4 cultures recorded under normoxia) *** 
indicates p ≤ 0.001 (ANOVA). 
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related (ATR), as well as the actin filament-stabilizing tropomodulin-1. In addition, 
the H/R adaptation induced the constitutive downregulation of the presumably 
antiapoptotic cytoglobin.  
Acute H/R induced higher mRNA abundances in the H/R-adapted as compared 
to the control PT cultures of the pro-apoptotic FADD (Fas-associated via death 
domain) and caspase-6, the stress-inducible Trp53inp1 (tumor protein p53-
inducible nuclear protein 1), and the uncoupling protein UCP-3. Glutathione 
peroxidase 2, in contrast, was more induced during acute H/R in control than in 
H/R-adapted PT cultures168.” 
 
 
s
e
le
c
ti
o
n
-a
s
s
o
c
ia
te
d
n
-f
o
ld
in
c
re
a
s
e
in
m
R
N
A
a
b
u
n
d
a
n
c
e
T
h
io
re
d
o
x
in
r e
d
u
c
ta
s
e
1
C
y
to
g
lo
b
in
A
ta
x
ia
te
la
n
g
ie
c
ta
s
ia
a
n
d
ra
d
3
re
la
te
d
S
u
p
e
ro
x
id
e
d
is
m
u
ta
s
e
2
,
m
it
o
c
h
o
n
d
ri
a
l
S
u
p
e
ro
x
id
e
d
is
m
u
ta
s
e
3
,
e
x
tr
a
c
e
llu
la
r
T
ro
p
o
m
o
d
u
lin
1
U
n
c
o
u
p
lin
g
p
ro
te
in
3
G
lu
ta
th
io
n
e
p
e
ro
x
id
a
s
e
2
0.1
1
10
3
0.3
C
a
s
p
a
s
e
6
S
u
rv
iv
in
F
A
D
D
P
Y
C
A
R
D
B
c
l-
1
0
T
rp
5
3
in
p
1
normoxia
hypoxia
Figure 12 - qPCR Analysis of Gene Expression H/R adaptation is associated with upregulation of mRNAs 
involved in oxidative defense, DNA-repair, apoptosis, and mitochondrial uncoupling. Comparison of mRNA 
abundances (quantitative RT-PCR microarrays) in control and H/R-adapted PT cultures after normoxic 
culture conditions (open bars)  and after hypoxia (48 h)/ reoxygenation (24 h) (closed bars) by quantitative 
RT-PCR microarrays. 
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“In addition, H/R-adapted PT cultures upregulated uncoupling protein-3 (UCP-3) 
mRNA, in particular, after acute H/R (Figure 13, A).” UCP-3 upregulation on 
mRNA basis was confirmed by qPCR. “Western blotting experiments confirmed 
that H/R induced also a significant upregulation of UCP-3 protein expression (~ 
4-fold increase) in the H/R-adapted but not in the control cultures (Figure 13, B 
and C)168.”  
“Since UCP-3 has been demonstrated to reduce mitochondrial ROS formation, 
to lower ischemia/reperfusion insults and to become upregulated by anaerobic 
muscle exercise (see discussion), upregulation of UCP-3 might directly contribute 
to the observed partial H/R resistance. Therefore, we knocked-down UCP-3 in 
control and H/R-adapted cultures by RNA interference (Figure 14, A) and 
determined mitochondrial superoxide formation and the subG1 fraction of 
propidium iodide-stained cells after normoxia or hypoxia (48 h)/ reoxygenation 
(24 h). A knockdown-mediated decrease by ~ 40% of UCP-3 protein abundance 
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Figure 13 - UCP-3 Expression H/R induces an up-regulation of the mitochondrial uncoupling protein-3 
(UCP-3) in H/R-adapted but not in control PT cultures. A. Mean (± SE, n = 3) GAPDH-normalized UCP-3 
mRNA abundance of control (open bars) and H/R-adapted PT cultures (closed bars) under normoxia (left) 
or after hypoxia (48 h)/ reoxygenation (24 h) as determined by quantitative RT-PCR. B. representative 
Immunoblot of PAGE-separated proteins from control (1st and 2nd lane) H/R-adapted PT cultures (3rd and 
4th lane) probed against UCP-3 and β-actin. Cell lysates were prepared from normoxic (upper blot) and 
cultures which underwent H/R stress (lower blot). C. Densitometrically semi-quantified increase in UCP-3 
protein of control (open bar) and H/R-adapted PT-cultures induced by hypoxia(48 h)/ reoxygenation (24 h; 
means ± SE, n = 3 cultures each; * indicates p ≤ 0.05, two-tailed Welch-corrected t-test) 
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significantly increased mitochondrial superoxide formation (Figure 14 B, C) in 
control and H/R-adapted PT cultures168.”  
“Moreover UCP-3 knock-down significantly lowered survival after H/R of the H/R-
adapted but not of the control PT cultures (Figure 15 A, B). This suggests that 
UCP-3 upregulation contributes to the H/R adaptation168.” 
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Figure 14 - Influence of UCP-3 Knock-Down on ROS Formation UCP-3 knock-down increases H/R-
induced superoxide production and cell death. A. Immunoblot showing the UCP-3 (upper gel) and - for 
loading control - the β-actin (lower gel) protein abundance in PT culture transfected with non-targeting (nt) 
RNA (left lane) or with UCP-3 siRNA (right lane). The ratio indicates the densitometrically semi-quantified β-
actin-normalized relative UCP-3 protein abundance. B. Histograms showing the MitoSOX fluorescence of 
nt- (black lines) and UCP-3 siRNA-transfected (red lines) PT cells after normoxia (top) or H/R stress (48 h 
hypoxia / 24 h reoxygenation, bottom), recorded as in Fig. 3. C. Mean normalized MitoSOX fluorescence 
intensities of nt- (open bars) and UCP-3 siRNA-transfected (closed bars) control and H/R-adapted PT 
cultures PT cells recorded in as in (B) under normoxic conditions or after H/R stress. Data are means ± SE, 
n = 6 from 2 cultures each determined in triplicate. 
 
Figure 15 - H/R-induced Cell Death after UCP-3 Knock-Down A. Histograms showing the propidium 
iodide fluorescence of permeabilized nt- (black line) and UCP-3 siRNA-transfected (red line) control (left) 
and H/R-adapted PT cultures (right) after hypoxia (48 h)/ reoxygenation (24 h, recorded as in Fig. 1). B. 
Mean percentage (± SE, n = 7-9 from 3 cultures each recorded in duplicate or triplicate) of dead cells (sub 
G1 population) in nt- (open bars) or UCP-3 siRNA-transfected control and H/R-adapted PT cultures after 
H/R stress (48 h hypoxia / 24 h reoxygenation. * and *** indicate p ≤ 0.05 and p ≤ 0.001, respectively 
(ANOVA). 
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3.5 UCP Expression in Renal Cell Carcinoma 
“To test whether UCP-3 might fulfill similar function in vivo, UCP-3 protein 
abundance was determined by immunoblotting in frozen specimens from human 
renal cell carcinoma (RCC) and normal renal 
tissue. Twentyseven tumor specimens (18 
clear cell RCCs (ccRCCs), 6 papillary RCCs 
(pRCCs) and 3 mixed clear cell/papipllary 
RCCs, median histological grading G = 2) as 
well as 15 non-cancerous renal specimens 
were selected form 21 patients that 
underwent (partial) nephrectomy. The 
patients (11 men, 10 women, mean age = 67 
± 2 years) developed large tumors ranging 
from 3 cm to 21 cm in diameter (mean 
diameter = 8 ± 1 cm). These tumors had 
large necrotic areas pointing to insufficient 
vascularization (Figure 16)168.”  
  
Figure 16 - RCC Specimen Human 
nephrectomy specimen top view (upper 
panel) and opened cut halves (lower 
panel) with renal cell carcinoma (RCC). 
Areas of necrosis and residual normal 
tissue, as well as locations of the 
sample taking are indicated (N: normal 
renal tissue, T: tumor without defined 
origin. TN: tumor close to necrotic area, 
TP: tumor at the periphery). 
5 cm
tumor
necrosisnormal tissue
N T
N
TP T
Results 38 
“The majority of tumor specimens showed various levels of UCP-3 protein 
abundance (Figure 17 A and B) that was on average significantly higher than in 
the non-cancerous renal samples indicating upregulation of UCP-3 during tumor 
development. Although some tumor specimens close to necrotic tumor areas 
(i.e., from presumed hypoxic regions, TN in Figure 17 A) showed extremely high 
UCP-3 protein abundance while peripheral tumor (TP in Figure 17 A) exhibited 
very low expression, the average UCP-3 abundance of TN specimens was not 
significantly different from that of the tumor samples of non-defined origin. No 
difference in UCP-3 protein abundance was found between ccRCS (Figure 17 B, 
red triangles) and pRCCs (Figure 17 B, blue triangles). In addition, univariate 
testing of the data suggested that UCP-3 abundance was not associated with 
patients’ age, gender, tumor size, occurrence of lymph node or distant 
metastasis, or histological tumor grading168.”  
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Figure 17 - UCP-3 Expression in RCC and Renal Tissue A. Immunoblot of renal cell carcinoma and 
normal renal tissue (as shown in A) probed against UCP-3 (2nd panel), GAPDH (3rd panel) and β-actin (4th 
panel). The 1st panel depicts the corresponding protein stain (PageBlue). The low or even missing 
housekeeper bands of the 4th and 8th sample (from left) might be explained by strong overexpression of 
other proteins by these two tumors. Since electrophoresis loading volume was adjusted to total protein 
concentration strong overexpression of some proteins dilutes the housekeeper proteins in these samples. 
Boxes indicate samples which originated from the same kidney. B. Scoring of the UCP-3 protein abundance 
in non-cancerous renal tissue (open circles) and clear cell RCCs (closed red triangles), papillary RCCs 
(closed blue triangles) or mixed RCCs (closed violet triangles). ** indicates p ≤ 0.01, Welch-corrected, two-
tailed t-test. 
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“To test whether RCCs similarly to UCP-3 upregulate other mitochondrial 
uncoupling proteins, UCP-1 and UCP-2 protein abundance was determined by 
immunoblotting in the RCC resection material (Figure 18). The results suggested 
downregulation of UCP-1 by all and upregulation of UCP-2 by some of the tested 
RCCs168.”  
“In addition, the ccRCC database of The Cancer Genome Atlas (TCGA) was 
queried for UCP-1, 2, and 3 mRNA expression of the tumor and survival of the 
ccRCC patients (Figure 19). The TCGA data suggest co-occurrence of high 
abundant UCP-2 and UCP-3 mRNA in the ccRCC specimens as well as shorter 
survival of ccRCC patients with high UCP-2 or UCP-3 mRNA abundance in the 
tumors as compared to the patients with “middle-rate” UCP expressions (Figure 
19). High abundance of UCP-1 mRNA, by contrast, was not associated with 
altered survival of the ccRCC patients. Since subgroup analysis concerning 
tumor staging, treatment regimes, etc. could not be performed, the conclusions 
drawn from the TCGA data is constrained. Nevertheless, the observed 
associations might point to a prognostic value of the UCP-3 or UCP-2 expression 
by the ccRCC. In addition, the data might hint to a functional redundancy of UCP-
2 and UCP-3168.” 
Figure 18 - UCP Expression in RCC and Renal Tissue Immunoblot of protein lysates from human RCC 
and adjacent normal tissue probed against UCP-1, UCP-2, UCP-3 and for loading control against β-actin 
(N: normal renal tissue, T: tumor without defined origin. TN: tumor close to necrotic area, TP: tumor at the 
periphery. Boxes indicate samples which originated from the same kidney). 
UCP-1
UCP-2
UCP-3
TP TN T NN T N T N
-actin
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3.6 H/R-adapted Cultures Exhibit Higher Resistance Against Ionizing 
Radiation 
Hypoxia resistance is associated with chemotherapy and irradiation resistance 
as shown before. “We therefore finally tested the possibility that increased UCP-
3 expression might be accompanied by increased resistance against anticancer 
therapies such as irradiation. To this end, control and H/R-adapted cultures were 
irradiated under normoxia with a single dose of 0, 5, or 10 Gy, and subG1 
population was recorded by flow cytometry (DNA staining of propidium iodide-
permeabilized cells applying the Nicoletti protocol) as a measure of cell death 24 
h and 48 h thereafter. As shown below (Figure 20), irradiated (10 Gy) H/R-
adapted cells died significantly less than irradiated control cells 48 h after 
irradiation. This suggests that adaptation to H/R leads to partial crossresistance 
against ionizing radiation possibly due to upregulation of DNA repair and 
oxidative defense (see Figure 12). The latter might mitigate the radiation-caused 
cellular lesions168.” 
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Figure 19 - Correlation Between Survival and UCP Expression Kaplan Meier plots showing the overall 
survival of ccRCC patients with high UCP-3 (A, red) or high UCP-2 mRNA-expressing tumors (C, red) in 
comparison with the respective control cohorts (blue). Patient numbers and p-values (log rank test) are 
indicated. 
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“To directly test for an involvement of UCP-3 in the acquired radioresitance of the 
H/R-adapted PT cultures, the effect of UCP-3 knockdown on radiogenic cell death 
was determined in control and H/R-adapted PT cultures 48 h after irradiation (0 
or 10 Gy) and 96 h after transfection with nt or UCP-3 siRNA, subG1 population 
of propidium iodide-stained cells was determined by flow cytometry (Figure 21 A, 
B). While having no effect on control cultures, UCP-3 knockdown increased 
slightly but significantly the fraction of dead cells caused by radiation (Figure 21 
B, C) showing an involvement of UCP-3 in radioresistance168.” 
Figure 20 - Cross Resistance of H/R-adapted Cultures Against Ionizing Radiation A. Histograms 
showing the propidium iodide fluorescence of permeabilized control (black) and H/R-adapted (red) PT cells. 
Cells were recorded by flow cytometry 48 h after irradiation (under normoxic conditions) with 0 Gy (top) or 
10 Gy (botom). The marker indicates the dead cells (sub G1 population). B. Percentage of dead cells (sub 
G1 population) in control (open bars) and H/R-adapted cultures (closed bars) 24 h (top) and 48 h (bottom) 
after irradiation (under normoxic conditions) with 0, 5, or 10 Gy. Data are means ± SE, n = 9 from 3 cultures 
each determined in triplicates. *** indicates p ≤ 0.001 (ANOVA).  
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Figure 21 - Effect of UCP-3 Downregulation on IR-induced Cell Death A. Propidium iodide histograms 
of nt RNA- (black) and UCP-3 siRNA (red) transfected H/R-adapted PT cells 48 h after irradiation with 0 Gy 
(left) or 10 Gy (right). B. Sub G1 population control (left) and H/R-adapted PT cultures (right) 96 h after 
transfection with nt or UCP-3 siRNA (as indicated) and 48 h after irradiation with 0 Gy (open bars) and 10 
Gy (closed bars). C. Radiation (10Gy) induced increase in Sub G1 population with nt (open bars) and UCP-
3 siRNA. Data are means ± SE, n = 6 from 2 cultures each determined in triplicates. * indicates p ≤ 0.05 
(ANOVA).  
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4 Discussion 
“UCP-3 uncoupling protein belongs to the mitochondrial anion transporter 
superfamily and is highly expressed in the mitochondrial inner membrane of 
brown adipose tissue, skeletal muscle and heart132,133,175. In the present study, 
selected, partially HR-resistant PT cultures differed from continuously normoxic 
grown control cultures by the expression of genes involved in DNA repair, 
apoptosis and oxidative defense and by the ability to up-regulate mitochondrial 
UCP-3 uncoupling protein during H/R stress.” This resulted in decreased 
oxidative stress and lower cell death in the selected cells. “Knockdown of UCP-3 
by RNA interference significantly attenuated the H/R resistance in the selected 
cultures while having no effect in the control cultures, showing a functional 
significance of this UCP-3 upregulation for the partial H/R resistance in the 
selected cultures” 
“As described above, an increasingly growing number of reports demonstrate that 
UCP-3 may lower mitochondrial ROS production by decreasing ∆Ψm as a “mild 
uncoupler”. This mild uncoupling function of UCP-3 is in particular evident from 
the observation that UCP-3 knockout results in increased mitochondrial ROS 
formation and oxidative damage of isolated skeletal muscle mitochondria or 
permeabilized muscle cells139,145,146,176. Importantly, chemical uncoupling in UCP-
3 knockout mitochondria partially mimics the function of UCP-3146. Moreover, 
UCP-3 knockout lowers fatty acid- or reactive aldehyde-stimulated increase in 
proton leak of the inner mitochondrial membrane136,177. Accordingly, 
overexpression of UCP-3 in myotubes decreases both ∆Ψm178–180 and 
mitochondrial ROS formation179.” 
“”In addition to these in vitro data, animal studies utilizing UCP-3 knockout or 
UCP-3 overexpressing mice demonstrated that UCP-3 decreases mitochondrial 
ROS-formation in fasted mice152,176 and protects from diet-induced obesity181 and 
insulin resistance155, two diseases associated with oxidative stress66,179. 
Moreover, downregulation of UCP-3 in rats with doxorubicin chemotherapy-
induced heart failure improves efficiency of cardial ATP synthesis at an expense 
of increased mitochondrial ROS formation182. Finally, UCP-3 knockdown 
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increased ischemia/reperfusion-induced mitochondrial ROS formation in the 
heart159. Again, chemical mitochondrial uncoupling partially compensated for 
UCP-3 function in the UCP-3 knock-out heart159. Combined, these data provide 
overwhelming evidence that UCP-3 lowers stress-induced mitochondrial ROS 
formation by preventing excessive hyperpolarization of ∆Ψm.” 
“However, the UCP-3-generated transports that may short-circuit the inner 
mitochondrial membrane are still ill defined. It has been suggested that UCP-3 
may export pyruvate183 and fatty acids including lipid radicals177,184  from the 
mitochondrial matrix along their electrochemical gradients. Besides lowering ∆Ψm 
and directly decreasing the concentration of lipid radicals in the matrix, pyruvate 
and fatty acids transports are thought to ensure an equilibrium between glycolysis 
and oxidative phosphorylation and to prevent Co-enzyme A shortage in the matrix 
and consecutive lipid-induced mitochondrial damage, respectively185,186. As a 
matter of fact, UCP-3 upregulation increases the efficiency of fatty acid oxidation 
in exercising muscle139. In accordance with that, in animal models and in human 
beings, fastening187,188, high fat diet189, or direct infusion of fatty acids188 have 
been demonstrated to upregulate UCP-3 expression, which is consistent with a 
specific function of UCP-3 in switching the metabolism from glucose to fatty acid 
respiration. A recent meta-analysis demonstrates an association between the 
55C/T polymorphism in the UCP-3 gene and obesity further suggesting such a 
UCP-3 function190.” 
“Other triggers of UCP-3 expression include (anaerobic) exercise of skeletal 
muscle139,140 and ischemia/reperfusion of the heart159,191. Likewise, oxidative 
stress following inhibition of glutathione reductase has been demonstrated to 
upregulate UCP-3 expression in rat myocardium192 where UCP-3 has been 
shown to be indispensable for ischemic preconditioning159. Moreover, reversible 
glutathionylation during oxidative stress is reportedly required to activate/inhibit 
UCP-3193. Together, these reported data indicate a function of oxidative-stress 
induced up-regulation of UCP-3 in mitigating ischemic/hypoxia-
reperfusion/reoxygenation injury of heart and skeletal muscle.” 
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“In the present study, UCP-3 upregulation was paralleled by an attenuated H/R-
mediated ∆Ψm hyperpolarization and mitochondrial superoxide formation of the 
PT cultures hinting to a UCP-3 function similar to that proposed in ischemic heart 
cells or anaerobic muscle contraction. UCP-3 protein was also upregulated in the 
majority of specimens from human renal cell carcinoma (RCC) as compared to 
the protein abundance of co-resected normal kidney tissue. Since clear cell RCC 
originates from neoplastic transformation of proximal tubular cells, it might be 
possible to speculate that UCP-3 in RCC might also confer resistance to H/R. 
One might further speculate that UCP-3-mediated hypoxia tolerance and survival 
of the tumor cells in hypoxic areas confers resistance to chemo- and radiation 
therapy: the wash-in of chemotherapeutics is hampered by the malperfusion and 
the efficacy of ionizing radiation is lowered by the low oxygen pressure of hypoxic 
tumors. Furthermore, the TGCA query of the present study hint to the possibility 
that high UCP-3 expression by the RCC might be associated with a poor 
prognosis.” 
“Similar to the upregulation of UCP-3 by RCC in the present study, other UCPs 
such as UCP-1, UCP-2, UCP-4 or UCP-5 are reportedly upregulated in a number 
of aggressive human tumors (leukemia, breast, colorectal, ovarian, bladder, 
esophagus, testicular, kidney, pancreatic, lung, and prostate cancer) where they 
are proposed to contribute to the malignant progression63. Moreover, UCP-2 
expression has been associated with paclitaxel resistance of p53 wildtype lung 
cancer162, CPT-11 resistance of colon cancer164, and gemcitabine resistance of 
pancreatic adenocarcinoma, non-small cell lung adenocarcinoma, or bladder 
carcinoma163. Accordingly, experimental targeting of UCPs has been 
demonstrated to sensitize tumor cells to chemotherapy in vitro63.”  
“In the present study, some RCC specimens exhibited elevated UCP-2 protein 
amounts compared to normal renal tissue. UCP-1 protein, in contrast, was 
downregulated in the RCCs. UCP-2 might exert a function in RCC similar to that 
proposed for UCP-3. This might be deduced from the TCGA database query of 
the present study which suggested that - likewise UCP-3 - high RCC UCP-2 
expression might be associated with bad prognosis.” 
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“In the present study, adaptation to H/R was accompanied by partial 
radioresistance. Knockdown of UCP-3 however, did only slightly increase 
radiation-induced cell death of the H/R-adapted PT cultures. Upon UCP-3 
knockdown the radiation-induced cell death of the control cultures was still much 
higher than in the selected cultures  suggesting that radioresistance in the H/R-
adapted PT cultures was substantially mediated by upregulation of DNA-repair 
and other oxidative defense mechanisms as seen in the PCR array.” 
“Ionizing radiation has been reported to upregulate UCP-2 expression in colon 
carcinoma cells194 and in a radiosensitive subclone of B cell lymphoma195, as well 
UCP-3 expression in rat retina196. Moreover, multi-resistant subclones of 
leukemia cells reportedly show higher UCP-2 protein expression, lower ∆Ψm, 
lower radiation induced formation of reactive oxygen species and decreased DNA 
damage as compared to their parental sensitive cells197. Combined, these 
reported data hint to a possible function of UCPs in the development of 
radioresistance also in other tumor entities.” 
“In conclusion, hypoxia/reoxygenation-tolerant PT cultures as well as renal cell 
carcinoma upregulate UCP-3 uncoupling protein in the inner mitochondrial 
membrane. UCP-3 upregulation attenuates at least in the in vitro PT model 
mitochondria-born oxidative stress during hypoxia/reoxygenation, and thus, 
confers partial hypoxia/reoxygenation resistance. Since tumor hypoxia promotes 
both, malignancy and therapy resistance, UCP-3 protein expression might be a 
prognostic and predictive marker in human neoplasms168.” 
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5 Summary 
“Tumor cells can adapt to a hostile environment with reduced oxygen supply. The 
present study aimed to identify mechanisms that confer hypoxia resistance. 
Partially hypoxia/reoxygenation (H/R)-resistant proximal tubular (PT) cells were 
selected by exposing PT cultures to repetitive cycles of H/R. Thereafter, H/R-
induced changes in mRNA and protein expression, inner mitochondrial 
membrane potential (m), formation of superoxide, and cell death were 
compared between H/R-adapted and control PT cultures. As a result, H/R-
adapted PT cells exhibited lower H/R-induced hyperpolarization of m and 
produced less superoxide than the control cultures. As a consequence, H/R 
triggered m break-down and DNA degradation in a lower percentage of H/R-
adapted than control PT cells. Moreover, H/R induced upregulation of 
mitochondrial uncoupling protein 3 (UCP-3) in H/R-adapted PT but not in control 
cultures. In addition, ionizing radiation killed a lower percentage of H/R-adapted 
compared to control cells suggestive of an H/R-radiation cross-resistance 
developed by the selection procedure. Knockdown of UCP-3 decreased H/R- and 
radioresistance of the H/R-adapted cells. Finally, UCP-3 protein abundance of 
PT-derived clear cell renal cell carcinoma and normal renal tissue was compared 
in human specimens indicating upregulation of UCP-3 during tumor development. 
Combined, our data suggest functional significance of UCP-3 for H/R 
resistance168.” 
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6 Zusammenfassung 
Tumorzellen können sich an ein hypoxisches Milieu anpassen. Die vorliegende 
Studie untersucht Mechanismen, die zu einer Resistenz gegenüber Hypoxie 
beitragen können. Partiell gegenüber Hypoxie/Reoxigenierung (H/R) 
unempfindliche proximale Tubuluszellen (PT) wurden durch repetitive Zyklen von 
Hypoxie und Reoxigenierung aus ursprünglichen PT-Kulturen 
herausselektioniert. Im Anschluss erfolgte eine Untersuchung der H/R 
induzierten Veränderungen hinsichtlich der mRNA- und Proteinexpression, des 
mitochondrialen Membranpotentials, der Bildung freier O2-Radikale und des 
induzierten Zelltodes verglichen mit den unselektionierten Kontrollkulturen. H/R-
angepasste Zellen zeigten eine geringere H/R bedingte Hyperpolarisierung des 
mitochondrialen Membranpotentials und eine geringere Bildung freier O2-
Radikale. In der Folge verursachte H/R bei den angepassten Zellen in einem 
geringeren Prozentsatz einen Zusammenbruch des Membranpotentials und der 
DNA-Degradierung. Zudem wurde durch H/R in den selektionierten Zellen das 
Uncoupling Protein 3 (UCP-3) im Vergleich zu den Kontrollzellen stärker 
exprimiert. Des Weiteren hatte Bestrahlung in den selektionierten Zellen eine 
geringere Wirkung als in den Kontrollzellen, was auf eine Kreuzresistenz durch 
den Selektionierungsprozess hindeutet. Eine Herunterregulation der UCP-3 
Expression führte zu einer Verringerung der Resistenz gegenüber H/R und 
Bestrahlung. Zuletzt erfolgte ein Vergleich der UCP-3 Expression in aus 
Tubuluszellen enstehenden klarzelligen Nierenzellkarzinomen und normalem 
Nierengewebe menschlichen Ursprungs. Zusammenfassend weisen die 
vorliegenden Daten auf die Bedeutung von UCP-3 für die H/R Resistenz hin.  
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